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Abstract
Introduction. The present study evaluated the interaction of statin response and genetic polymorphism of interleukin 
(IL-1β, IL-6, IL-4, IL-10) genes with the course of atherosclerosis and coronary heart disease (CHD) in patients with 
CHD combined with acute respiratory viral infections (ARVI).
Objectives. Studying variability of Rosuvastatin response in patients with CHD combined with ARVI, taking cytokine 
gene polymorphism into account.
Materials and methods. Detection of lipid metabolism parameters and interleukin levels in blood serum; verification 
of causative agents of the infectious process. Genotyping of polymorphisms IL-1β –511C>T, IL-6 –174G>C, IL-4 
–589C>T, IL-10 –1082G>А. Statistical processing in Microsoft Office Excel 2007 software.
Results and discussion. In CHD patients at Visit I, the target level of low-density lipoprotein cholesterol (LDL-C) was 
reached by 55.7% of participants. At Visit II, the target LDL-C level was reached by 49.7% of patients, which coincided 
with ARVI detection in some patients.
In CHD patients with ARVI at Visit II, the IL-1β level increased to 33.00 pg/ml (N=5.00 pg/ml), IL-6 – 19.20 pg/ml 
(N=9.00 pg/ml); at Visit VI those levels decreased to 20.70 pg/ml and 12.80 pg/ml. The IL-4 level was 8.30 pg/ml 
(N=13.00 pg/ml), while IL-10 level was 19.40 pg/ml (N=31.00 pg/ml), with their increase at Visit VI to 15.80 pg/ml 
and 33.50 pg/ml.
CHD patients without ARVI did not develop interleukin level changes. At Visit II, the IL-1β level was 10.30 pg/ml, 
IL-6 level was 12.40 pg/ml, and at Visit VI, they were 13.00 pg/ml and 14.00 pg/ml. The IL-4 and IL-10 levels at Visit 
II were 19.70 pg/ml and 32.30 pg/ml; at Visit VI, those levels were 23.20 pg/ml and 34.20 pg/ml. The following asso-
ciations were demonstrated: –511CT / increased IL-1β, LDL-C synthesis; –511СС / LDL-C level increase; –174GG / 
IL-6, LDL-C level increase; –1082GG / IL-10 level increase, cholesterol and CRP level decrease; –589ТТ / CRP, IL-4 
level increase.
Conclusion. Genotypes –511CT, –174GG, –1082AA in all patients required 20 mg/day Rosuvastatin dose to reach the 
target LDL-C level.
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Introduction
CHD continues to be leading in the structure of mortality 
and disability among diseases of the cardiovascular sys-
tem (CVS).
In 2017, 53.3% lethal outcomes in the Russian Federa-
tion are attributed to CHD (Boytsov et al. 2017).
Absence of drug response to pharmacological hyperli-
pidemia (HLP) correction is diagnosed in every fifth pa-
tient (Sychev 2011).
Being a multifactorial disease, CHD is associated with 
genetic factors and environmental factors; it is also sub-
ject to chronopharmacology laws. According to the re-
sults of epidemiological studies, chronic CHD destabili-
zation was detected in different seasons (Pankrushina and 
Sudakova 2014).
There is a seasonal trend in the increase in the number of 
hospitalizations for patients with CHD, due to intercurrent 
infections in autumn and spring (Surnin et al. 2011, Gribo-
vskaya et al. 2015). Pharmacotherapy of patients in these 
conditions is changed compared to the standard manage-
ment. This requires a search for modern pharmacological 
approaches to correct the treatment in this patients’ group.
One of the main pathogenetic causes of atherosclerosis 
development is inflammation, being an important athero-
genesis component (Surnin et al. 2011, Gribovskaya et al. 
2018) (Fig. 1).
Inflammation is a sign of the impact of various factors 
damaging vascular endothelium. A number of studies de-
monstrate the relation between an increase in the proin-
flammatory cytokine level (TNF-а, IL-1β, IL-6) and the 
signs of atherosclerosis destabilization and CHD (Golysh-
ko 2010, Pankrushina and Sudakova 2014, Shevchenko 
2015). Any acute infection may be the etiological factor 
which activates chronic inflammation in the atheroscle-
rotic plaque, involving the cytokine system (Pankrushina 
and Sudakova 2014, Gribovskaya et al. 2015).
Quite a few articles demonstrate the relation between 
the clinical and laboratory status of CHD patients who 
have had ARVI and influenza (Golyshko 2010, Surnin et 
al. 2015, Gribovskaya et al. 2018).
An infectious process acts as a trigger that destabilizes 
the course of atherosclerosis and CHD. There is laborato-
ry and instrumental evidence for this (Surnin et al. 2011, 
Pankrushina and Sudakova 2014). However, no endogen-
ous components, which are essential for cardiovascular 
destabilization, have been studied.
ARVI is characterized by the imbalance of cytokine 
interaction against the background of chronic infection 
(herpes virus, cytomegalovirus), which becomes irrever-
sible with the inflammatory process activation (Zykov et 
al. 2011, Surnin et al. 2011). Thus, pharmacological HLP 
correction should be changed considering the aggravating 
background (concomitant viral infection).
The present study evaluated the relation between gene-
tic polymorphism of pro- and anti-inflammatory cytokine 
genes (IL-1β, IL-6, IL-4, IL-10) and a statin response de-
gree. Besides, changes of patient’s biochemical, immuno-
logical, and morphometric statuses were monitored in 
various Rosuvastatin dose regimens.
Failure to reach the target LDL-C level in the studied 
patients was associated with insufficient intensity of 
Figure 1. Pathogenesis of atherosclerosis.
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Rosuvastatin pleiotropic effects in CHD patients in pre-
sence of an acute infectious illness.
Consequently, genetic aspects caused by interleukin 
gene polymorphism impact the implementation of pleiot-
ropic statin effects, ensuring patients’ compliance with 
HLP pharmacotherapy.
Thus, before the start of treatment, genetic tests are re-
quired to possibly predict its efficacy, i.e. achieving the 
target LDL-C level. This will enable individualization of 
HLP pharmacotherapy in this patients’ group.
Objectives: to study drug response variability when 
evaluating hypolipidemic and pleiotropic Rosuvastatin 
effects in CHD patients and in those where it is combined 
with an acute infectious illness.
Materials and methods
The study involved 170 CHD patients, 120 of whom also 
had infections (ARVI).
The inclusion criteria for the patients were as fol-
lows: males and postmenopausal females aged 41-60 
years; stable angina of functional class (FC) I-II (Di-
agnostics and correction of lipid metabolism disorders 
in order to prevent and treat atherosclerosis. Russian 
recommendations of the All-Russian Scientific Socie-
ty of Cardiologists (V revision) 2018); acute infectious 
process caused by influenza virus, cytomegalovirus 
(CMV), or Chlamydia pneumoniae; isolated or com-
bined hypercholesterolemia – HC (patients with chole-
sterol level>5.5 mmol/l, triglycerides>1.7 mmol/l) (Di-
agnostics and correction of lipid metabolism disorders 
in order to prevent and treat atherosclerosis. Russian 
recommendations of the All-Russian Scientific Society 
of Cardiologists (V revision) 2018); no contraindica-
tions to HMG-CoA-reductase inhibitors; prior therapy 
with 4th generation statins as hypolipidemic treatment, 
with starting dose of 10 mg/day; patient informed con-
sent for study participation.
The exclusion criteria were as follows: individual 
Rosuvastatin intolerability; side effects of the treatment 
administered (3-fold liver enzyme increase); patient’s 
refusal to continue the treatment; comorbid diseases re-
quiring pharmacotherapy which could impact lipid me-
tabolism.
HC was verified based on the inclusion criteria, the 
presence of increased lipid metabolism parameters, as 
well as subclinical and clinical atherosclerosis signs. 
The patients with secondary lipid metabolism parameters 
were excluded from the study.
CHD disease and FC of stable angina were confirmed 
according to the clinical signs and the exercise stress test 
performed in pre-hospital settings.
The study was performed using a simple prospective me-
thod. The design was approved at the meeting of the Regio-
nal Ethics Committee of KSMU on 12th May 2017 (Fig. 2).
All the patients underwent a standard general clinical 
examination. At each study point, the LDL-C and choles-
terol (C) levels were determined in the blood serum using 
an enzymatic calorimetric method and diagnostic “Analyti-
con” kits manufactured by Vitalab Flexor E (Netherlands).
HLP pharmacotherapy was performed using 4th gene-
ration statins (Rosuvastatin, starting dose of 10 mg/day) 
according to the recommendations (Diagnostics and cor-
rection of lipid metabolism disorders in order to prevent 
and treat atherosclerosis. Russian recommendations of 
the All-Russian Scientific Society of Cardiologists (V re-
vision) 2018).
Visit I: screening and inclusion of CHD patients into 
the study.
Visit II: dividing the patients into 2 subgroups based of 
the target LDL-C level (determined at the moment of hos-
pitalization of some patients with ARVI into the Regional 
Clinical Infectious Hospital) to be reached.
If the target LDL-C level (1.8 mmol/l) was not rea-
ched during Rosuvastatin administration on Day 7 from 
ARVI onset (Visit III) (Diagnostics and correction of lipid 
metabolism disorders in order to prevent and treat ather-
osclerosis. Russian recommendations of the All-Russian 
Scientific Society of Cardiologists (V revision) 2018), the 
patient was switched to the 20 mg/day dose. On subse-
quent visits, reaching the target LDL-C level was chec-
ked, with further dose titration.
Infection verification was performed based on the cli-
nical signs, using virological (polymerase chain reaction 
(PCR) of nasopharyngeal smears) and immunological 
(enzyme-linked immunosorbent assay (ELISA) of blood 
serum) methods. The virological spectrum was as fol-
lows: CMV – 29.1%, Influenza А – 40.1%, and Chlamy-
dia pneumoniae – 30.8%.
Taking into account the detected causative agent, phar-
macotherapy of the main disease included, according to 
the recommendations (Clinical protocols. National Scien-
tific Society of Infectiologists 2014), the following: anti-
viral drugs (Oseltamivir – 0.75 g BID, Umifenovir – 0.2 
g QID) and antibiotics in case of bacterial complications 
(macrolides: Azithromycin – 0.5 g OD, or 3rd generation 
cephalosporins – Ceftriaxone 1.0 g BID i/m). Sympto-
matic treatment included antipyretics – anilides (Parace-
tamol 0.5 g). Oseltamivir was administered in 19% of 
cases, Ceftriaxone – in 40% of cases, Azithromycin – in 
23% of cases, and Umifenovir – of in 81% cases.
Interleukin concentration in blood serum was deter-
mined using an ELISA method on a Tecan analyzer, using 
Vector Best CJSC kits.
Genomic deoxyribonucleic acid (DNA) isolation 
was performed on frozen (-20°С) venous blood using 
phenol-chloroform extraction. Genotyping of poly-
morphisms IL-1β –511C>T (annealing t -57°С, Mg – 
3.5), IL-6 –174G>C (annealing t -45°С, Mg – 2.5), IL-4 
–589C>T (annealing t -57°C, Mg – 2.5), IL-10 –1082G>А 
(annealing t -51°С, Mg – 2.5) was performed using a 
PCR method on a CFX96 Bio-Rad Laboratories ampli-
fier (USA) with commercial TaqMan SNP Genotyping 
Assays reagent kits manufactured by Applied Biosystems 
(USA). The DNA isolation method was developed at the 
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Department of Biology, Medical Genetics, and Ecology 
of KSMU.
To confirm statistical significance of thye obtained results, 
Microsoft Excel Office 2007 software package was used. 
The character of quantitative feature distribution and nor-
mality were evaluated using Student t-test. The parameters 
were considered statistically significant at the level P<0.05. 
To detect the power and direction of relations between the 
features under study, the correlation analysis was performed, 
with the calculation of the correlation coefficient (r).
Results and discussion
This research, conducted in the comparable subgroups of 
CHD patients with ARVI and those without ARVI, evalu-
ated the efficacy of HLP pharmacotherapy when applying 
Rosuvastatin monotherapy (10 mg/day).
CHD patients at Visit I demonstrated the hypolipide-
mic effect of Rosuvastatin (10 mg/day) in the form of 
55.7% patients achieving the target LDL-C level, out of 
whome isolated HC was found in 30.1% of the patients, 
and combined HC – in 25.6% of the patients.
Four weeks after inclusion into the study (Visit II), an 
individual evaluation of hypolipidemic efficacy correcti-
on was performed, based on achieving the target LDL-C 
level. At this visit, some cases of patients being hospita-
lied into the Regional Clinical Infectious Hospital with 
ARVI signs were registered.
Thus, the signs of CHD destabilization were the chan-
ged lipid profile parameters, with voiding the LDL-C 
level previously reached using a standard Rosuvastatin 
dose (10 mg/day).
At Visit II, a decrease in the achieved target level was 
detected in 61.7% CHD patients, among whom 33.1% of 
patients had isolated HC, and 28.6%of CHD patients had 
combined HC.
The clinical signs of CHD destabilization were not re-
gistered, which was confirmed by consequent electrocar-
diogram (ECG) registration over time.
The data obtained on destabilization of the atheroscle-
rosis course facilitated the change of the standard treat-
ment with the titration of the used Rosuvastatin dose.
The patients were followed up 7 days (Visit III), 14 
days (Visit IV), 28 days (Visit V), and 3 months (Visit VI) 
after the ARVI onset, according to the study design.
Starting from Visit II, the patients underwent HLP 
treatment adjustment with Rosuvastatin 10 mg/day and 
Rosuvastatin 20 mg/day. The percentage of CHD patients 
with ARVI and isolated HC evaluated at Visit III demon-
Figure 2. Design of the statin therapy study in patients with CHD with and without ARVI.
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strated that 50% of patients had reached the target LDL-C 
level when taking 10 mg Rosuvastatin and 55% patients 
– when taking a 20 mg dose (Fig. 3).
The subsequent follow-up points demonstrated the tar-
get cholesterol level was reached in 53% and 60% (Visit 
IV), in 58% and 63% (Visit V), in 64% and 67% patients 
(Visit VI) when applying the corresponding dose regimens.
In CHD patients with ARVI and combined HC, at Vi-
sit III, 47% of patients reached the target level on 10 mg 
Rosuvastatin and 52% – on 20 mg dose (Fig. 4).
Further follow-up showed that the target LDL-C level 
was reached in 50% and 56% (Visit IV), 56% and 60% (Vi-
sit V), 62% and 64% (Visit VI) of patients. Thus, the dose 
regimen adjustment for statin therapy up to 20 mg of Rosu-
vastatin promoted an increase of its hypolipidemic effect.
Pharmacological HC correction was performed in 
CHD patients without ARVI signs within the same period 
(Fig. 5).
In CHD patients with isolated HC, Rosuvastatin at a 
dose of 10 mg dose facilitated reaching the target LDL-C 
level in 54% (Visit I), 50% (Visit II), 54% (Visit III), 57% 
(Visit IV), 60% (Visit V), and 65% (Visit VI) of patients.
Accordingly, Rosuvastatin at a dose of 20 mg to re-
aching the target LDL-C level in 60% (Visit III), 64% 
(Visit IV), 68% (Visit V), and 72% (Visit VI) of patients.
For CHD patients with combined HC, at Visits I and II, 
HLP pharmacotherapy with Rosuvastatin at a dose of 10 
mg/day led to reacing the target LDL-C level in 43% and 
46% patients (Fig. 6). With further dose regimen correcti-
on, at Visit III, the target level (Rosuvastatin aministered 
at a dose of 10 mg/day) was reached in 50% of patients, 
and in 58% of patients – at a 20 mg/day dose.
Visit IV was characterized by 53% of patients (10 mg/
day) and 62% participants (20 mg/day) reaching the target 
level. At Visit V, the target level was reached in 56% (10 
mg/day) and in 66% (20 mg/day) of patients. At Visit VI, 
69% (20 mg/day) and 60% patients (10 mg/day) reached 
the target cholesterol level.
With pharmacological correction of HLP with Rosu-
vastatin, the hypolipidemic effect criterion was demon-
strated with 67% of the studied patients reaching the 
target LDL-C level on Week 12 of pharmacotherapy 
(Fig. 7).
Along with the lipid metabolism parameters, the 
morphometric parameters (intima media thickness (IMT) 
of commons carotid arteries (CCA)) were also studied. 
The IMT examination allowed evaluating the efficacy of 
HLP pharmacotherapy (Table 1).
In the CHD patients included into the study, the IMT de-
termined in the outpatient settings did not exceed 1.50 mm.
In CHD patients with ARVI, IMT at Visit I was 
1.23±0.10 mm. Further pharmacotherapy with Rosu-
vastatin at a dose of 10 mg/day led to a decrease in IMT 
to 1.15±0.05 mm at Visit VI, and with Rosuvastatin at a 
dose of 20 mg – to 1.00±0.01 mm.
Thus, treatment with different doses of Rosuvastatin 
facilitaed a significant IMT decrease when applying the 
both dose regimens.
An IMT decrease in CHD patients with ARVI (pI-
VI<0.05) at Follow-up Week 12 was 7%, which was sig-
nificant for patients who had reached the target LDL-C 
level when taking Rosuvastatin at a dose of 10 mg/day 
and 20 mg/day.
In CHD patients with ARVI, IMT at Visit I was 
1.15±0.02 mm, and at Visit VI, against the background 
of HLP pharmacological correction with Rosuvastatin, it 
was 1.10±0.10 mm (10 mg/day) and 1.00±0.30 mm (20 
mg/day) (Table 2).
Figure 3. Percentage of patients with comorbid pathology 
(CHD with isolated HC + ARVI) who reached the target LDL-C 
level against the background of Rosuvastatin treatment using 
different dose regimens.
Figure 4. Percentage of patients with comorbid pathology (CHD 
with combined HC + ARVI) who reached the target LDL-C lev-
el against the background of Rosuvastatin treatment using dif-
ferent dose regimens.
Figure 5. Percentage of CHD patients with isolated HC, but 
without ARVI, who reached the target LDL-C level against the 
background of Rosuvastatin treatment using different dose reg-
imens.
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The analysis of IMT changes in the CHD patients 
without ARVI (pI-VI<0.05), when Rosuvastatin is admi-
nistered at a dose of 10 mg/day, showed IMT regression 
by 9%, while with 20 mg administration (pI-VI<0.05) – by 
8.8%. No statistically significant differences were detec-
ted in the groups among the CHD patients with isolated 
and combined HC, but without ARVI.
Thus, a more significant pleiotropic effect was detected 
for Rosuvastatin administered at 20 mg/day in CHD pa-
tients with or without ARVI.
However, to achieve IMT regression in patients with 
comorbid diseases, Rosuvastatin dose titration up to 20 
mg/day was required for the majority of patients (63%), 
which was inferior to the data obtained in CHD patients 
without ARVI (68%).
The obtained data accorded with those from large-sca-
le multicenter trials, e.g. ASTEROID (2005), ORION 
(2005), METEOR (2006), SATURN (2011), which eva-
luated Rosuvastatin impact on atherosclerotic plaque re-
gression. However, disease duration in those studies was 
at least two years, while the used doses of Rosuvastatin 
reached 40-80 mg QD, without taking acute inflammation 
(Melnyk et al. 2010, Skvortsov et al. 2013).
While studying the changes of hypolipidemic and 
pleiotropic components of Rosuvastatin pharmacological 
effect, their relations and interdependence were of great 
interest (Fig. 8).
Evaluation of relations between IMT in different Rosu-
vastatin dose regimens and lipid panel parameters demon-
strated that there was a direct and very weak correlation 
between IMT and C when Rosuvastatin was administered 
at a dose of 10 mg. After titration of Rosuvastatin dose to 
20 mg/day, a weak correlation relationship was diagnosed 
between IMT and C.
When studying IMT and LDL-C level changes during 
HLP pharmacotherapy with Rosuvastatin at a dose of 10 
Figure 6. Percentage of CHD patients with combined HC, but with-
out ARVI, who reached the target LDL-C level against the back-
ground of Rosuvastatin treatment using different dose regimens.
Figure 7. Proportion of patients who reached the target LDL-C 
level.
Table 1. Dynamics of IMT Decrease in Examined Patients at Week 12 (M±m, n=120)
CCA IMT I (mm) Dose CCA IMT VI (mm) CCA IMT I-VI P
1.23±0.10
10 mg 1.15±0.05 0.02±0.22 0.050
20 mg 1.00±0.01 0.27±0.50 0.001
Table 2. Dynamics of IMT decrease in the studied CHD patients without ARVI at Week 12 (M±m, n=50)
CCA IMT I (mm) Dose CCA IMT VI (mm) CCA IMT I-VI P
1.15±0.02
10 mg 1.10±0.10 0.10±0.06 0.04
20 mg 1.00±0.30 0.15±0.16 0.03
mg/day, a direct and very weak correlation was observed. 
Rosuvastatin administered at a dose of 20 mg provided 
for a weak correlation relationship between LDL-C and 
IMT.
In the context of pleiotropic statin effect, studying an 
anti-inflammatory activity is of utmost interest, along 
with studying a hypolipidemic one.
Pathogenetic mechanisms of atherosclerotic process 
progression are related to the participation of viral agents 
(direct cytopathic action on the vascular wall with the de-
velopment of endothelial dysfunction) (Loktionova et al. 
2012). Thus, when causative agent permeates, the activity 
of immune cells increases, and chronic inflammation is 
activated in atherosclerotic plaques (Loppnow et al. 2011, 
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Shevchenko 2015). Consequently, ARVI is a predictor of 
atherosclerosis progression.
The interleukin levels in blood serums were determin-
ed in CHD patients at Visit II and further on, during the 
follow-up up to Week 12 (Visit VI) (Fig. 9).
Cytokine profile follow-up in CHD patients with ARVI 
when administering Rosuvastatin at a dose of 10 mg re-
vealed an increase in the interleukin-1 level to 33.00 pg/
ml at Visit II, with ARVI verification compared to the 
normal one (5.00 pg/ml), with a further decrease At Visit 
VI (3 months after ARVI), it was 20.70 pg/ml after HLP 
pharmacotherapy.
The IL-6 level at Visit II was 19.20 pg/ml, with a fu-
rther decrease to 12.80 pg/ml. The cytokine profile data 
obtained at Visit II in CHD patients with ARVI were cau-
sed by the activation of inflammatory processes at the mo-
ment of viral infection onset.
Further changes of pro-inflammatory cytokine para-
meters towards a progressive decrease were related to 
specific features of the clinical status of ARVI patients 
(transition to reconvalescence period, starting from Day 
7 – Visit III) and implementation of Rosuvastatin pleiot-
ropic effects.
Pro-inflammatory cytokine (IL-4 and IL-10) levels in 
CHD patients with ARVI at Visit II were characterized by 
low parameters. Thus, the IL-4 level at Visit II was 8.30 
pg/ml, with a subsequent increase at Visit VI to 15.80 pg/
ml. The IL-10 level at Visit II was 19.40 pg/ml, while at 
Visit VI it increased to 33.50 pg/ml.
These changes were due to manifestations of active in-
flammatory process at Visit II, with the trend to further 
restore cytokine status balance by the end of the fol-
low-up (Week 12).
Three months after a viral infection, the patients re-
ached the cytokine levels comparable with the results 
obtained in CHD patients without viral infection signs 
(p>0.05).
CHD patients without ARVI signs revealed a slight va-
riability of the pro-inflammatory interleukin parameters 
throughout the 12-week case follow-up (Fig. 10).
The IL-1β level fluctuated from 10.30 pg/ml at Visit II 
to 13.00 pg/ml at Visit VI. The IL-6 parameter changed 
from 12.40 pg/ml at Visit II to 14.00 pg/ml at Visit VI.
The IL-1β and IL-6 levels were characterized by stable 
parameters throughout the whole follow-up period and 
were significantly lower than those in CHD patients with 
viral infection (p<0.05).
This pattern can be explained by stable balance of 
pro-inflammatory cytokines during the chronic inflamma-
tory process in chronic CHD patients without infection 
(Loppnow et al. 2011, Zykov et al. 2011).
The IL-4 and IL-10 parameters in CHD patients without 
ARVI signs were significantly higher (P˂0.05) compared 
to the group of CHD patients with ARVI (Fig. 10). This is 
due to the suppression of inflammation in the atheroscle-
Figure 8. Relations of lipid profile parameters with IMT changes in different dose regimens.
Figure 9. Features of cytokine background level in CHD pa-
tients with ARVI.
Note:* - Р<0,05 for the t-Student test
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rotic plaque due to blocked secretion of pro-inflammatory 
cytokines. Such a pattern is explained by the activation 
of compensatory mechanisms to maintain the balance in 
case of chronic CHD (Gribovskaya et al. 2018).
The anti-inflammatory IL-4 was characterized by a sta-
ble level – 19.70 pg/ml at Visit II and 23.20 pg/ml at Visit 
VI. The IL-10 level fluctuated from 32.30 pg/ml at Visit II 
to 34.20 pg/ml at Visit IV.
The values of the studied cytokine system parameters 
confirmed stable atherosclerosis course in CHD patients 
without concomitant infections, with the implementation 
of pleiotropic statin effects.
As known, cytokines participate in atherosclerosis and 
CHD development (Golyshko 2010).
Consequently, the research of polymorphisms of cyto-
kine genes impacting protein production and its function 
has a great value for revealing pathogenetic mechanisms 
and the ways to manage them.
For this purpose, the genotyping of IL-1β, IL-6, IL-4, 
IL-10 gene polymorphisms was performed. The following 
genotypes were obtained: IL-1β –511C>T, (–511CC, 
–511CТ, –511ТТ), IL-6 –174G>C (–174GG, –174GC, 
–174CC), IL-4 –589C>T (–589СС, –589СТ, –589ТТ), 
IL-10 –1082G>А (–1082AA, –1082AG, –1082GG). The 
distribution of genotype frequencies corresponded to the 
Hardy-Weinberg law.
To study pathogenetic components impacting the drug 
response, the presence of relations between specific geno-
types of pro-/anti-inflammatory cytokines, their parame-
ters, and the patients’ lipid profile was evaluated (Fig. 11).
The analysis of –511C>T polymorphism of the IL-1β 
gene revealed the association of –511CT genotype of the 
IL-1β gene with an increased production of this interleu-
kin at Visit II – 33.00 pg/ml (P<0.05) (Whayne 2015).
Studying the impact of IL-1 concentration on the li-
pid fraction level revealed a direct weak relation (r=0.46, 
P<0.05) between the levels of C and IL-1. The highest 
LDL-C levels – 2.54 mmol/l (p<0.05) were observed in 
carriers of heterozygous –511СТ genotype of the IL-1 gene.
As known, IL-6 regulates the response of the acute in-
flammation phase (Guan et al. 2012, Shevchenko 2015). 
For the IL-6 gene, –174GG genotype demonstrated the 
most significant effect on the production of this cytoki-
ne. Its blood serum concentration at Visit II increased to 
32 pg/ml compared to other genotypes of the IL-6 gene 
(P<0.05), which agrees with data from foreign trials 
(Chen et al. 2012).
The analysis of association of IL-6 gene genotypes 
with the quantitative lipid level showed that in carriers 
of –174GG genotype, the LDL-C level exceeded such for 
other IL-6 genotypes – 2.51 mmol/l (P<0.05). This proved 
the destabilization of the lipid transport system in case of 
acute inflammation (Babu et al. 2012) and the insufficient 
intensity of lipid- and non-lipid effects of Rosuvastatin at 
a dose of 10 mg/day, which showed in failure to reach the 
target LDL-C level.
It was shown that the presence of –589 C/Т poly-
morphism of the IL-4 gene located in the promotor region 
led to replacing cytosine (C) for thymine (T) in positi-
on –589, with an increased transcriptional gene activity 
(Chen et al. 2012, Shevchenko 2015).
Thus, for carriers of the homozygous –589СС geno-
type of the IL-4 gene, the anti-inflammatory activity of 
IL-4 decreased (Shevchenko 2015). In the present study, 
IL-4 and CRP production was increased in carriers of the 
–589ТТ genotype compared to the presence of other ge-
notypes (P<0.05).
IL-10, which suppresses the production of pro-inflam-
matory cytokines and antigen-presenting functions of ma-
crophages, serves as a cellular immunity inhibitor. The 
presence of G/G genotype of the G-1082A locus is related 
to the anti-inflammatory immunity activation (Chen et al. 
2012). Detection of homozygous А/А genotype was asso-
ciated with low IL-10 production (r=0.32, P=0.01), which 
led to prolonged preservation of an increased number of 
pro-inflammatory cytokines and an increased inflamma-
tory process chronicity (Babu et al. 2012). The present 
study demonstrated IL-10 synthesis in carriers of homo-
zygous –1082GG genotype.
The analysis of impact of genetic polymorphisms of 
pro- and anti-inflammatory cytokine genes in CHD pa-
Figure 10. Features of cytokine background level in CHD pa-
tients without ARVI.
Note: * - Р<0,05 for the t-Student test
Figure 11. Correlation genotype analysis for pro-/anti-inflam-
matory cytokines and lipid profile parameters in CHD patients 
with ARVI.
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tients without ARVI on the pharmacological response of 
Rosuvastatin at a dose of 10 mg/day revealed a weak di-
rect correlation between the IL-1β and IL-6 levels (10.30 
pg/ml and 12.40 pg/ml) and –511TT and –174GC geno-
types, respectively (r=0.46, P=0.001) (Fig. 12).
Carriers of – 511TT genotype were diagnosed with the 
lowest LDL-C level and a high HDL-C level (p<0.05), 
which confirmed the implementation of a hypolipidemic 
Rosuvastatin effect. Carriers of –511СС genotype had the 
increased LDL-C levels.
Carriership of homozygous –1082GG genotype de-
monstrated the association with the decreased CRP and 
the level of C (r=0.6, P=0.003), which confirmed the ac-
tivation of anti-inflammatory processes in patients with 
chronic inflammation. When the anti-inflammatory cyto-
kine (IL-4, IL-10) level increased, the C level decreased 
(r=0.47, P<0.05).
The analysis of correlation between pro-/anti-inflam-
matory cytokine gene genotypes revealed the activity of 
genotypes –511TT (IL-1β gene), –174CC (IL-6 gene), 
–589TT (IL-4 gene), and –1082GG (IL-10 gene) in main-
taining chronic inflammation stability (r=0.46, P=0.012).
Thus, one can parallel the implementation of the an-
ti-inflammatory Rosuvastatin effect in CHD patients with 
ARVI. The anti-inflammatory effect is due to genetic 
polymorphism of pro-/anti-inflammatory cytokine genes 
(Chen et al. 2012, Yu et al. 2012).
The obtained correlations contributed to the preparati-
on of a personalized HLP pharmacotherapy algorithm in 
CHD patients in presence of ARVI (Fig.13).
Conclusion
1. APersonalized approach to HLP pharmacotherapy in 
CHD patients in presence of an acute infectious pro-
cess proved the necessity of Rosuvastatin dose titration 
to 20 mg/day in order to reach the target LDL-C level 
in 27% of patients, who failed to responding to a 10 
mg/day dose.
2. The presence of heterozygous –511CT genotype for 
–511C>T polymorphism of the IL-1β gene, homozy-
gous –174GG genotype for –174G>C polymorphism 
of the IL-6 gene, and homozygous –1082AA genotype 
for polymorphism –1082G>A of the IL-10 gene did not 
lead to reaching the target LDL-C level in Rosuvasta-
tin 10 mg/day monotherapy.
3. Carriership of these genotypes required pharmacothe-
rapy with Rosuvastatin 20 mg/day to reach the target 
LDL-C level.
4. 33% of the studied patients who had higher levels of 
lipid transport system parameters at the moment of in-
clusion into the study did not reach the target LDL-C 
levels on HLP pharmacotherapy with Rosuvastatin 20 
mg/day.
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